Yi, Shuhua
Cai, Zhen
Hu, Yu
He, Aili
Gao, Sujun
Li, Qian
Sha, Linlin
Zhang, Nating
Ren, Yupeng
Gai, Xue
Yang, Xue
Qin, Rui
Qiu, Lugui
Clinical trials referenced in this document:
Documents that mention this clinical trial
Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study
https://doi.org/10.1007/s12325-023-02720-w
Funding for this research was provided by:
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2022-I2M-1–022)
Janssen Research & Development, LLC
Janssen Global Services
Article History
Received: 8 August 2023
Accepted: 26 October 2023
First Online: 11 December 2023
Declarations
:
: Lugui Qiu receives consultation fees and honoraria from Xian Janssen Pharmaceutical Ltd, Pfizer, Beigene, and Roche. Qian Li, Linlin Sha, Nating Zhang, Yupeng Ren, Xue Gai, Xue Yang, and Rui Qin are employees of Johnson & Johnson. Xue Yang and Rui Qin report stock ownership from Johnson & Johnson. Shuhua Yi, Yu Hu, Zhen Cai, Aili He, and Sujun Gao have nothing to disclose.
: This study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and local applicable regulatory requirements. All patients provided written informed consent according to the local requirements prior to enrollment. The trial protocol and any amendments were reviewed and approved by an independent ethics committee at each investigation site.